Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

Sponsor: Tahir Latif

Sponsor score: 0

ClinicalTrials ID:NCT03688451

This clinical trial evaluates the safety and feasibility of administering rituximab intrathecally alongside methotrexate for CNS prophylaxis in patients with CD20+ diffuse large B-cell lymphoma. Eligible participants are those at high risk of CNS relapse, currently receiving systemic rituximab with CHOP, CHOEP, or EPOCH. The intervention involves rituximab delivered intrathecally over 3-5 minutes.

Patient Parameters

Program Overview

The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.

Eligibility Criteria

Inclusion Criteria

  • CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS relapse and eligible for central nervous system prophylaxis with intrathecal therapy.

Exclusion Criteria

  • Primary central nervous system lymphoma or established secondary central nervous system disease.
  • History of spinal surgery and/or ineligible for intrathecal injections.

Locations

FACILITYZIPCITYSTATE
UC Health45219CincinnatiOhio

Get This Program In Your Inbox

You can sign up and apply your patients for this program.